The shares of the UK-based biopharmaceutical Adaptimmune Therapeutics have had a rough year, with its stock down more than 35% between the beginning of January and mid-August of this year. In comparison, the SP500 index was up more than 20% at the same time.

On September 7th, UK-based biopharmaceutical, Adaptimmune's stock jumped almost 29% following the news that it has signed a collaboration deal worth up to $3 billion with Genentech.

As part of the deal, Adaptimmune will receive $150 million in cash upfront, $150 million more over the next five years, and developmental, regulatory, and commercial milestones potentially worth more than $3 billion. In addition, the company will receive royalties from the products they develop.